ArticleDiabetes, obesity & metabolism2026
A Type 2 Diabetes Policy Model That Predicts Remaining Life Expectancy, Quality-Adjusted Life Expectancy and Healthcare Costs for Use in Economic Evaluation, Incorporating Equity Concerns.
Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
aimsTo illustrate a T2DM policy model incorporating socio-economic status. MATERIALS AND
methodsUsing the Scottish Diabetes Research Network (SDRN) national diabetes cohort, we identified individuals newly diagnosed with T2DM between 1 January 2004 and 31 December 2020 and followed from diagnosis until death or end of follow-up. Covariates included sex, Scottish Index of Multiple Deprivation (SIMD) quintiles, ethnicity, HbA1c, systolic blood pressure (SBP), eGFR, total cholesterol, high-density lipoprotein, BMI, smoking status and cardiovascular disease history. Remaining life expectancy was modelled using Gompertz regression, stratified by sex and SIMD. Probabilities of complications were estimated using repeated measure logistic regression, and healthcare costs were modelled using repeated measure linear regression. A parameterised Kaplan-Meier sample-average estimator was used to obtain life expectancy, quality-adjusted life years (QALYs) and costs.
resultsWe identified 269 759 people newly diagnosed with T2DM. The mean age at diagnosis was 63 years, 56% were male and 24% lived in the most deprived areas. Total follow-up was 2 090 108 patient-years (median 7 years per patient). Approximately one in four patients died during follow-up. The most common T2DM-related complications were coronary heart disease and heart failure. For a man diagnosed at age 50 in the most deprived quintile, with all other covariates at average values, the model predicted a remaining life expectancy of 26.7 years, 21.1 QALYs and healthcare costs of £273 k (undiscounted). For the same profile, the incremental cost-effectiveness ratio for a hypothetical intervention reducing HbA1c by 1% was £7832 per QALY.
conclusionsWe developed a T2DM policy model incorporating socio-economic deprivation, providing estimates of life expectancy, QALYs and healthcare costs to inform health technology assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.